India to United States: Amikacin Export Trade Route

To import Amikacin formulations into the United States, the following approvals and registrations are mandatory:

• Drug Approval Applications: The product must have an FDA-approved application, such as a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA).

• Establishment Registration and Drug Listing: Foreign drug manufacturers must register their establishments with the FDA and list all drug products intended for commercial distribution in the U.S.

• Import Entry Procedures: Importers are required to file an entry notice and an entry bond with U.S. Customs and Border Protection (CBP). The FDA reviews these entries to determine the admissibility of the products.

• Labeling Compliance: All imported drug products must comply with FDA labeling requirements, which include providing accurate and complete information to ensure proper use.

• Good Manufacturing Practice (GMP) Inspections: Indian manufacturing facilities producing Amikacin formulations must comply with FDA's GMP regulations. The FDA may conduct inspections to verify compliance.

Indian exporters of Amikacin formulations must adhere to the following GMP standards:

• GMP Certification: Manufacturers must comply with the FDA's GMP regulations, ensuring that products meet quality and purity standards.

• Facility Inspections: The FDA conducts inspections of foreign manufacturing facilities to assess compliance with GMP standards. For instance, in April 2024, the FDA completed an inspection of Lupin's Dabhasa facility in India with no observations, indicating full compliance.

• Regulatory Actions: Non-compliance can result in regulatory actions. In June 2024, the FDA issued a warning letter to an Indian sterile manufacturer due to significant GMP deficiencies, including insanitary conditions and inadequate maintenance.

Recent developments affecting Indian pharmaceutical exports to the United States include:

• Increased Scrutiny: Following incidents involving substandard products, the FDA has intensified inspections and enforcement actions against Indian pharmaceutical manufacturers to ensure compliance with quality standards.

• Regulatory Updates: The FDA has updated guidelines and import alerts to address emerging risks and ensure the safety and efficacy of imported pharmaceutical products.

Compliance with these regulatory requirements is essential for the successful importation of Amikacin formulations into the United States.

In 2024, the U.S. aminoglycosides market, which includes amikacin formulations, was valued at approximately $641.2 million. Projections indicate growth to $814.4 million by 2030, reflecting a compound annual growth rate (CAGR) of 4.2% from 2025 to 2030.

The demand for amikacin formulations is driven by the increasing incidence of multidrug-resistant gram-negative infections, particularly in hospital settings. These infections necessitate the use of aminoglycosides like amikacin in severe cases, such as ventilator-associated pneumonia and sepsis. Additionally, the aging U.S. population, which is more susceptible to infections and undergoes more surgical procedures, contributes to the heightened demand for these antibiotics.

While specific data on the proportion of amikacin formulations imported versus domestically manufactured in the United States is not readily available, the importation of these formulations, including those from India, plays a significant role in meeting domestic demand.

Pharmaceutical products under HS code 30049099, including amikacin formulations, are imported into the United States duty-free under the MFN status. There are no additional import duties, value-added tax (VAT), or goods and services tax (GST) applied to these products upon entry into the U.S. market.

Currently, there is no Free Trade Agreement (FTA) between India and the United States that specifically affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on amikacin formulations imported from India.

India is a major supplier of amikacin formulations to the United States, accounting for a significant portion of the imports. Other notable suppliers include countries within the European Union and China. However, specific data on the exact market share of these countries in the U.S. amikacin import market is not readily available.

India's pharmaceutical industry is known for its cost-effective manufacturing capabilities, often offering competitive pricing compared to European Union manufacturers. This pricing advantage, combined with the quality of products, positions India as a key player in the U.S. amikacin formulations market.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing capability extends to finished dosage forms containing Amikacin, including injections and other formulations. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of November 2024, India had 134 FDA-registered facilities for finished dosage forms, underscoring its significant role in the global pharmaceutical industry.

When comparing Amikacin formulation exports, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. India's cost-effective production is due to lower labor and operational expenses. While China is a major supplier of active pharmaceutical ingredients (APIs), its finished dosage form exports are limited, and concerns about regulatory compliance have been noted. (iris.who.int) The EU, known for high-quality branded generics, often has higher production costs, leading to more expensive products. India's pharmaceutical products are widely accepted in the United States, with numerous FDA-approved facilities ensuring compliance with stringent regulatory standards.

India's pharmaceutical industry demonstrates robust manufacturing capacity for finished dosage forms, including Amikacin formulations. The country has invested in advanced packaging and cold chain logistics to maintain product integrity during transit. Recent FDA approvals, such as the one granted to Granules Life Sciences' Hyderabad facility in November 2025, reflect India's commitment to regulatory compliance and capacity expansion. While occasional supply disruptions have occurred, the industry's proactive measures and continuous improvements have enhanced supply chain reliability.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amikacin formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers may have varying MOQs; it's essential to negotiate terms that align with your procurement needs and inventory management strategies.

• Establish Favorable Payment Terms: Common payment terms in India-United States pharmaceutical trade include letters of credit and advance payments. Negotiating terms that balance cash flow considerations with supplier requirements is crucial.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on FDA approvals, compliance with Good Manufacturing Practices (GMP), production capacity, and quality control systems to ensure product quality and regulatory adherence.

• Monitor Regulatory Compliance: Stay informed about regulatory changes and ensure that suppliers maintain compliance with both Indian and United States pharmaceutical regulations to avoid potential disruptions.

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a minimum of 3-5 days on-site, with additional time for travel and reporting.
• Estimated costs include auditor fees, travel expenses, and accommodation, typically ranging from $10,000 to $15,000 per audit.

By adhering to this comprehensive approach, United States companies can effectively qualify Indian suppliers of Amikacin formulations, ensuring compliance with regulatory standards and the delivery of high-quality pharmaceutical products.